Systemic Lupus Erythematosus: An Overview

Social Work in Health Care

Volumn 51, Issue 7, 2012, Pages 576-586

  Askanase, Anca ^a   Shum, Katrina ^a   Mitnick, Hal ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diagnosis; lupus; medical; treatment

Indexed keywords

ANTIMALARIAL AGENT; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; FEMALE; GENETICS; HUMAN; MALE; PREVALENCE; SEX RATIO; STATISTICS; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

AFRICAN AMERICANS; AGE DISTRIBUTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; BIOLOGICAL AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREVALENCE; SEX DISTRIBUTION; STEROIDS; SURVIVAL ANALYSIS;

EID: 84865198517     PISSN: 00981389     EISSN: 1541034X     Source Type: Journal    
DOI: 10.1080/00981389.2012.683369     Document Type: Article

References (36)

1. Alarcon-Segovia, D., Alarcon-Riquelme, M.E., Cardiel, M.H., Caeiro, F., Massardo, L., Villa, A.R. and Pons-Estel, B.A. 2005. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis & Rheumatism, 52(4): 1138-1147.
2. Allison, A.C. and Eugui, E.M. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47(2-3): 85-118.
3. Arnett, F.C. and Shulman, L.E. 1976. Studies in familial systemic lupus erythematosus. Medicine (Baltimore), 55(4): 313-322.
4. Austin, H.A. 3rd, Klippel, J.H., Balow, J.E., le Riche, N.G., Steinberg, A.D.Plotz, P.H. 1986. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. New England Journal of Medicine, 314(10): 614-619.
5. Bernatsky, S., Boivin, J.F., Joseph, L., Manzi, S., Ginzler, E.Gladman, D.D. 2006. Mortality in systemic lupus erythematosus. Arthritis & Rheumatism, 54(8): 2550-2557.
6. Bielschowsky, M., Helyer, B.J. and Howie, J.B. 1959. Spontaneous haemolytic anemia in mice of the NZB/BL strain. Proceedings of the University of Otago Medical School, 37(9)
7. Blotzer, J.W. 1983. Systemic lupus erythematosus I: Historical aspects. Maryland State Medical Journal, 32(6): 439-441.
8. Chakravarty, E.F., Bush, T.M., Manzi, S., Clarke, A.E. and Ward, M.M. 2007. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis & Rheumatism, 56(6): 2092-2094.
9. Deicher, H.R., Holman, H.R. and Kunkel, H.G. 1959. The precipitin reaction between DNA and a serum factor in systemic lupus erythematosus. Journal of Experimental Medicine, 109(1): 97-114.
10. Friou, G.J. 1957. Clinical application of lupus serum-Nucleoprotein reaction using the fluorescent antibody technique. Journal of Clinical Investigation, 36(6): 890-890.
11. Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J.Merrill, J.T. 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New England Journal of Medicine, 353(21): 2219-2228.
12. Hanly, J.G. 2008. The neuropsychiatric SLE SLICC inception cohort study. Lupus, 17(12): 1059-1063.
13. Hargraves, M., Richmond, H. and Morton, R. 1948. Presentation of two bone marrow elements: The tart cell and the LE cell. Proceedings of the Staff Meeting of the Mayo Clinic, 23: 25
14. Hench, P.S. 1952. The reversibility of certain rheumatic and nonrheumatic conditions by the use of cortisone or of the pituitary adrenocotropic hormone. Annals of Internal Medicine, 36(1): 1-38.
15. Hochberg, M.C. 1987. The application of genetic epidemiology to systemic lupus erythematosus. Journal of Rheumatology, 14(5): 867-869.
16. Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 40(9): 1725
17. Holborow, E.J., Weir, D.M. and Johnson, G.D. 1957. A serum factor in lupus erythematosus with affinity for tissue nuclei. British Medical Journal, 2(5047): 732-734.
18. Kaposi, M. 1872. Neue Beitrage zur Keantiss des lupus erythematosus. Archives of Dermatology and Syphilology, 4: 36
19. Lahita, R.G. 1999. The role of sex hormones in systemic lupus erythematosus. Current Opinion in Rheumatology, 11(5): 352-356.
20. Lahita, R.G. 2004. Systemic Lupus Erythematosus, 4th, Amsterdam, Holland and Boston, MA: Elsevier Academic Press.
21. Lim, S.S., Drenkard, C., McCune, W.J., Helmick, C.G., Gordon, C.Deguire, P. 2009. Population-based lupus registries: Advancing our epidemiologic understanding. Arthritis & Rheumatism, 61(10): 1462-1466.
22. Manzi, S., Selzer, F., Sutton-Tyrrell, K., Fitzgerald, S.G., Rairie, J.E.Tracy, R.P. 1999. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis & Rheumatism, 42(1): 51-60. doi:10.1002/1529-0131(199901)42:1<51:AID-ANR7>3.0.CO;2-D
23. Michel, M., Johanet, C., Meyer, O., Frances, C., Wittke, F.Michel, C. 2001. Familial lupus erythematosus. Clinical and immunologic features of 125 multiplex families. Medicine (Baltimore), 80(3): 153-158.
24. Moore, J.E. and Lutz, W.B. 1955. The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactors. Journal of Chronic Diseases, 1(3): 297-316.
25. Moser, K.L., Kelly, J.A., Lessard, C.J. and Harley, J.B. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. Genes and immunity, 10(5): 373-379.
26. Navarra, S.V., Guzman, R.M., Gallacher, A.E., Hall, S., Levy, R.A.Jimenez, R.E. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet, 377(9767): 721-731.
27. Olser, W. 2009. On the visceral manifestations of the erythema group of skin diseases [Third Paper.] 1904. American Journal of the Medical Sciences, 338(5): 396-408.
28. Payne, J. 1894. A post-graduate lecture on lupus erythematosus. Clinical Journal, 4: 223
29. Pescovitz, M.D. 2006. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. American Journal of Transplantation, 6(5 Pt 1): 859-866.
30. Plosker, G.L. and Figgitt, D.P. 2003. Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 63(8): 803-843.
31. Radcliffe-Crocker, H. 1898. Discussion on lupus erythematosus. British Journal of Dermatology, 10: 375
32. Smith, C.D. and Cyr, M. 1988. The history of lupus erythematosus. From Hippocrates to Osler. Rheumatic Disease Clinics of North America, 14(1): 1-14.
33. Talbott, J. 1993. "Historical background of discoid and systemic lupus erythematosus". In Lupus erythematosus, 4th, Edited by: Wallace, D.J., Hahn, B. and Dubois, E.L. 3-11. Philadelphia: Lea & Febiger.
34. Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J.Rothfield, N.F. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 25(11): 1271-1277.
35. Urowitz, M., Gladman, D., Ibanez, D., Fortin, P., Bae, S.Gordon, C. 2011. Evolution of disease burden over 5 years in a multicentre inception SLE cohort. Arthritis Care & Research (Hoboken).,
36. Urowitz, M., Ibanez, D. and Gladman, D. Changing Outcomes in SLE Over 35 Years. Paper presented at the 2005 ACR/ARHP Annual Scientific Meeting, San Diego, CA. November.